Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

PC9细胞系是一种从非小细胞肺癌患者的腺癌组织中分离培养而成的细胞系。 PC9细胞系的特点是携带有EGFR敏感突变，是EGFR-TKI（酪氨酸激酶抑制剂）治疗药物的一个优良的模型系统。 该细胞系对于厄洛替尼和吉西他滨等其他非 EGFR-TKI 类药物的敏感性并不高。 值得注意的是，近年来，研究者发现PC9细胞系抗药突变的患者血液样本中存在着高频血清性突变，称为C797S突变。 这一突变会导致EGFR抑制剂治疗的耐药性，因此，研究者将其作为耐药性评估的关键细胞 …

该 生物资源中心通过短串联重复序列(STR) DNA分析发现该细胞系与PC-9 相同,PC-9 是源自人肺腺癌( 分化型) 的细胞系。 此错误识别发生在细胞系存放在RIKEN 生物资源中心之前。 细胞系的名称更改为PC-9,以反映这一发现。 完全培养液配方: 见下方备注。 批次/ 冻存日期: 详见冻存管/培养瓶标识. 1. 人肺腺癌细胞PC-9 完全培养液配方(100 ml):RPMI 1640 Medium (Invitrogen, 11875-093) 2. 我库冻存时,每 支冻存管约含7 105 细胞量,体 积为500 μl,预 期存活率70%,建议复苏至1 …

In this study, we introduced the EGFR T790M mutation into the PC9 human lung cancer cell line—which has a deletion in exon 19 of the EGFR gene—by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)9-mediated genome editing.

Erlotinib-resistant PC-9 (PC-9ER) cells arose following chronic exposure to erlotinib through the acquisition of the secondary EGFR mutation, T790M. Gefitinib-resistant PC-9 (PC-9GR) cells were obtained by chronic exposure to gefitinib through activation of …

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) are widely used for the treatment of non-small cell lung cancers (NSCLCs) harboring EGFR -activating mutations. However, lung cancer cells inevitably acquire resistance to these EGFR-TKIs.

放在RIKEN生物资源中心。该生物资源中心通过短串联重复序列 (STR) DNA 分析发现该细胞系与 PC-9 相同,PC-9 是源自人�. 腺癌(分化型)的细胞系。此错误识别发生在细胞系存放在. RIKEN 生物资源中心之前。细胞系的名称更�. 养液配方:见下方备注。 批次/冻存日期. 1. 否完全挥发等异常现象。如发现问题,请拍照�. 等),并尽快核销或报销。请勿用. 擅自更换培养液体系。 (1 )如订购冻存状态的细胞,请将收到的细胞冻存管转移至-80度低温冰箱或液氮罐. 时,并镜下观察细胞状态 …

2025年3月31日 · The scRNA-seq data of PC9 cell line under drug treatment at multiple time points was obtained from GEO with accession number GSE149383. The scRNA-seq data of PCa cell line was obtained from GEO ...

2025年3月17日 · Cell plates were acquired and analyzed using a Tecan microplate reader and data was represented as percentage of viable cells. A549 or PC9 cells were treated with SAHA/Vorinostat (Selleckchem.com, Cat# S1047), BML-281 (Avantor®, Cat#76002-128) or WT161 (Cayman Chemical, Cat# 21099), and analyzed for Annexin V …

2024年11月20日 · Results: PC-9 EGFRD19/T790M/C797S cells, with the EGFRD19/T790M/C797S mutation, were successfully generated using CRISPR/Cas9 technology. In terms of proliferation inhibition, the marketed first-, second-, and third-generation EGFR-TKIs that were ineffective against the EGFRD19/T790M/C797S mutation showed weak proliferation inhibitory activity ...